Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... La Jolla, CA (PRWEB) August 19, 2014 ... the toll Parkinson’s disease can take on an individual. ... tremoring extremities, decreased facial expression, problems swallowing and severe ... due to the dying off of dopamine producing neurons ... retain themselves from a disease that slowly and progressively ...
(Date:8/19/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... novel C. difficile development program will ... Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September ... Synthetic Biologics, Senior Vice President, Research ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... they are riddled with defects, bulk crystalline materials never ... are so small there,s no room for defects. ("Nano" ... Yet while nanocrystalline materials may approach ideal strength in ... a limited ability to withstand large internal strains before ...
... Oct. 20 Humanitarian, Dr. Gary Michelson,is "making ... Aimee Gilbreath, Executive Director of Found Animals Foundation ... Found Animals and its strategic partner the ... the launch of The Michelson Prize in,Reproductive Biology ...
... 20 Idenix,Pharmaceuticals, Inc., (Nasdaq: IDIX ) announced ... third quarter of 2008 on Thursday, October,30, 2008 after ... the issuance of the press release, Idenix,management will host ... October,30, 2008 to discuss the company,s financial results for ...
Cached Biology Technology:Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... 19, 2014 -- Bay Area Lyme Foundation, which aims ... to cure, applauds new research published in an upcoming ... and Tick-borne Diseases . The findings show that ... active throughout the year, making the threat of Lyme ... California Department of Public Health (CDPH) Vector-borne Disease Section ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... treat tumors by selectively targeting and killing the malignant ... access journal PLoS Medicine, has applied the approach to ... form of brain tumour, growing very quickly before symptoms ... of diagnosis. , Working in mice, Alexander Levitzki ...
... There was a low rate of life-threatening adverse ... first responders to a bioterrorism incident, possibly attributable ... according to a study in the December 7 ... smallpox in the United States ceased in 1971, ...
... Bees have a much more sophisticated visual system than ... London) study in which bees were able to solve ... brains resolve one of the most difficult challenges of ... of illumination - by suggesting that bees solve this ...
Cached Biology News:Preclinical study of a new brain tumor therapy 2Serious adverse reactions to smallpox vaccine appear to be limited 2Bees solve complex colour puzzles 2
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... low background fluorescence, minimal light scatter ... medium binding) polystyrene surface is hydrophobic ... passive interactions,• Is suitable primarily ... such as antibodies, that have large ...
... microplate washer, 100-240 V, is used for ... or V-bottom wells. This washer has programmability ... an accuracy of 0.1 mm for bottom ... can store up to 75 wash sequences ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: